Therapeutic cancer vaccines derived from a novel dendritic cell line
AssigneeDcprime B.V.
InventorsSandra Van Wetering, Adriana Kruisbeek
Life of this patent
Estimating the term…
Abstract
The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.
Claims17
A method for obtaining modified cells, the method comprising:
- incubating a precursor cell line as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012, under conditions that allow differentiation of the precursor cells into immature cells;
- and
- incubating the immature cells under conditions that allow maturation of the immature cells into modified cells, wherein the modified cells are CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.
A method for obtaining modified cells, the method comprising:
- differentiating a precursor cell line as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012, to produce modified cells, wherein the modified cells are CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.
Dependencies are inferred from the claim text.